153 related articles for article (PubMed ID: 32460978)
1. Myelodysplastic/myeloproliferative neoplasms - Justified inclusion as unique biological entities.
Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101135. PubMed ID: 32460978
[No Abstract] [Full Text] [Related]
2. Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM; Padron E
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
4. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
Niemeyer CM; Kratz CP
Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies.
Sakaguchi H; Makishima H; Muramatsu H; Visconte V; Jerez A; Jankowska AM; Tiu RV; Maciejewski JP; Kojima S
Leuk Res; 2012 Dec; 36(12):e215-7. PubMed ID: 22748922
[No Abstract] [Full Text] [Related]
6. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
[TBL] [Abstract][Full Text] [Related]
7. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
Emanuel PD
Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
[TBL] [Abstract][Full Text] [Related]
8. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
9. [The classification and therapy of myelodysplastic/myeloproliferative neoplasms (MDS/MPN)].
Hata T; Miyazaki Y
Nihon Rinsho; 2012 Apr; 70 Suppl 2():342-6. PubMed ID: 23133979
[No Abstract] [Full Text] [Related]
10. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
Carr RM; Patnaik MM
Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
[TBL] [Abstract][Full Text] [Related]
11. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
12. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
13. Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?
Tefferi A
Leuk Lymphoma; 2008 Jul; 49(7):1225-7. PubMed ID: 18604709
[No Abstract] [Full Text] [Related]
14. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
15. Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M; Della Porta MG; Gallì A; Panini N; Licandro SA; Bello E; Craparotta I; Rosti V; Bonetti E; Tancredi R; Rossi M; Mannarino L; Marchini S; Porcu L; Galmarini CM; Zambelli A; Zecca M; Locatelli F; Cazzola M; Biondi A; Rambaldi A; Allavena P; Erba E; D'Incalci M
Br J Cancer; 2017 Jan; 116(3):335-343. PubMed ID: 28072764
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
17. [Progress in research of the pathogenesis of childhood MDS/MPN].
Yoshida K
Rinsho Ketsueki; 2018; 59(10):2284-2289. PubMed ID: 30305537
[TBL] [Abstract][Full Text] [Related]
18. CMML: Clinical and molecular aspects.
Itzykson R; Duchmann M; Lucas N; Solary E
Int J Hematol; 2017 Jun; 105(6):711-719. PubMed ID: 28455647
[TBL] [Abstract][Full Text] [Related]
19. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
Orazi A; Germing U
Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
[TBL] [Abstract][Full Text] [Related]
20. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
